🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the effort against superbug strains of the bacteria, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are increasing worldwide, with figures suggesting over 82 million infections annually. Notably increased rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the face of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”

Health officials are increasingly worried about the surge in antibiotic-resistant strains. The WHO has classified it as a "critical concern". A tracking program found that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

One new antibiotic, alternatively called Nuzolvence, was cleared by the US FDA in mid-December for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts anticipate that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in the same week. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This approval signifies a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

Based on results detailed in a major medical journal, zoliflodacin eradicated over nine in ten of uncomplicated infections. This puts it on an comparable level with the typical regimen, which uses an injection and a pill. The study enrolled over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the ability to make available and distribute the drug in numerous regions with limited resources.

Medical professionals on the front lines have shared positive views. The availability of a single-dose, oral treatment like this is seen as a "critical tool" for gonorrhoea control. This is considered vital to alleviate the strain of the disease for people and to stop the proliferation of highly drug-resistant gonorrhoea around the world.